title: Assessing efficacy and therapeutic claims in emerging indications for recombinant factor VIIa: regulatory perspectives.
abstract: When compared with the evidence-based, cost-effectiveness criteria underpinning most government reimbursement schemes in the social market economies, the three regulatory hurdles of safety, quality and efficacy are probably of modest impact in influencing increased usage of recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark). Nevertheless, efficacy claims must be supported if regulatory approval is to be granted for the wider range of indications that have been proposed for rFVIIa. With the refinement of clinical trial designs over the past 40 years, the randomized controlled trial (RCT) has assumed the role of gold standard, providing the highest level of evidence for therapeutic efficacy. However, it is incorrect to assume that regulatory authorities give sole credence to RCTs in assessing claims. It is noteworthy that the indications already accepted for rFVIIa by international regulatory authorities--including the treatment of inhibitors to factor VIII and factor IX, substitution for FVII deficiency, and treatment of Glanzmann's thrombasthenia--were supported not by RCTs but by studies conventionally considered to provide modest evidence levels. Therefore, the use of studies other than RCTs for the more recently proposed indications for rFVIIa in a range of conditions requiring hemostatic correction is perfectly feasible. What regulators expect are well-conducted and well-described studies adhering to principles of good clinical practice, which can be scrutinized for evidence of clinical efficacy and which are based on the initially proven principle for the drug. This paper discusses the regulatory history of rFVIIa in the major regulatory authorities and assesses the route needed to support claims being made in the mainstream literature. Recent episodes where post-market events have forced regulators to be more than usually cautious will be used as examples to suggest possible pitfalls to the extension of approved claims for rFVIIa. The major paths for enhancing access for indications in small patient numbers, where RCTs are even more difficult to perform, will be described and their use for possible extension of rFVIIa indications will be discussed.
authors.affiliation: Therapeutic Goods Administration, Woden, Australia. albert.farrugia@health.gov.au
authors.forename: Albert
authors.initials: A
authors.lastname: Farrugia
mesh_terms: D001777:Blood Coagulation / Q000187:drug effects; D005167:Factor VII / Q000191:economics / Q000266:history / Q000627:therapeutic use*; D015942:Factor VIIa; D006291:Health Policy / Q000191:economics / Q000266:history / Q000331:legislation & jurisprudence; D049673:History, 20th Century; D006801:Humans; D011994:Recombinant Proteins / Q000191:economics / Q000266:history / Q000627:therapeutic use; D013915:Thrombasthenia / Q000188:drug therapy* / Q000191:economics / Q000266:history; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa